Evidence map›Paper›PMID 36605212›Full record

ArticleFrontiers in immunology2022

HLA variants have different preferences to present proteins with specific molecular functions which are complemented in frequent haplotypes.

Vadim Karnaukhov, Wayne Paes, Isaac B Woodhouse, Thomas Partridge, Annalisa Nicastri, Simon Brackenridge, Dmitrii Shcherbinin, Dmitry M Chudakov, Ivan V Zvyagin, Nicola Ternette and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. A journey to your self: The vague definition of immune self and its practical implications.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  17. New light on the HLA-DR immunopeptidomic landscape.Journal of leukocyte biology · 2024
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Vadim KarnaukhovCenter of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russia.
Wayne PaesNuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.
Isaac B WoodhouseMedical Research Council (MRC) Human Immunology Unit, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine (WIMM), John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Thomas PartridgeNuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.
Annalisa NicastriThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Simon BrackenridgeNuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.
Dmitrii ShcherbininShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Science, Moscow, Russia.
Dmitry M ChudakovCenter of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russia.
Ivan V ZvyaginShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Science, Moscow, Russia.
Nicola TernetteThe Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Hashem KoohyMedical Research Council (MRC) Human Immunology Unit, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine (WIMM), John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Persephone BorrowNuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.
Mikhail ShugayShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Science, Moscow, Russia.
University of Oxford · GBInstitute of Bioorganic Chemistry · RUJenner Institute · GBSkolkovo Institute of Science and Technology · RUMedical Research Council · GBMRC Human Immunology Unit · GBPirogov Russian National Research Medical University · RU

Funding

Targeting 5' leader-encoded defective ribosomal products for HIV T cell vaccinesR01AI118549 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2016 to 2020
$3.6M
Medical Research Council MR/K012037NIAID NIH HHS R01 AI118549
6 · The paper itself

Abstract

Human leukocyte antigen (HLA) genes are the most polymorphic loci in the human genome and code for proteins that play a key role in guiding adaptive immune responses by presenting foreign and self peptides (ligands) to T cells. Each person carries up to 6 HLA class I variants (maternal and paternal copies of HLA-A, HLA-B and HLA-C genes) and also multiple HLA class II variants, which cumulatively define the landscape of peptides presented to T cells. Each HLA variant has its own repertoire of presented peptides with a certain sequence motif which is mainly defined by peptide anchor residues (typically the second and the last positions for HLA class I ligands) forming key interactions with the peptide-binding groove of HLA. In this study, we aimed to characterize HLA binding preferences in terms of molecular functions of presented proteins. To focus on the ligand presentation bias introduced specifically by HLA-peptide interaction we performed large-scale in silico predictions of binding of all peptides from human proteome for a wide range of HLA variants and established which functions are characteristic for proteins that are more or less preferentially presented by different HLA variants using statistical calculations and gene ontology (GO) analysis. We demonstrated marked distinctions between HLA variants in molecular functions of preferentially presented proteins (e.g. some HLA variants preferentially present membrane and receptor proteins, while others - ribosomal and DNA-binding proteins) and reduced presentation of extracellular matrix and collagen proteins by the majority of HLA variants. To explain these observations we demonstrated that HLA preferentially presents proteins enriched in amino acids which are required as anchor residues for the particular HLA variant. Our observations can be extrapolated to explain the protective effect of certain HLA alleles in infectious diseases, and we hypothesize that they can also explain susceptibility to certain autoimmune diseases and cancers. We demonstrate that these differences lead to differential presentation of HIV, influenza virus, SARS-CoV-1 and SARS-CoV-2 proteins by various HLA alleles. Taking into consideration that HLA alleles are inherited in haplotypes, we hypothesized that haplotypes composed of a combination of HLA variants with different presentation preferences should be more advantageous as they allow presenting a larger repertoire of peptides and avoiding holes in immunopeptidome. Indeed, we demonstrated that HLA-A/HLA-B and HLA-A/HLA-C haplotypes which have a high frequency in the human population are comprised of HLA variants that are more distinct in terms of functions of preferentially presented proteins than the control pairs.

Indexed as

HaplotypesHLA-A AntigensHLA-B AntigensHLA-C AntigensHumansPeptidesHLA-A AntigensHLA-B AntigensHLA-C AntigensPeptidesgene ontologies and pathwaysHLAmass spectrometrymolecular functionprotein

Identifiers

PMID36605212
PMCPMC9808399
OpenAlexW4312078670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.